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The b1-adrenergic-receptor (ADRB1) antagonist metoprolol reduces infarct size in acute
myocardial infarction (AMI) patients. The prevailing view has been that metoprolol acts
mainly on cardiomyocytes. Here, we demonstrate that metoprolol reduces reperfusion injury
by targeting the haematopoietic compartment. Metoprolol inhibits neutrophil migration in an
ADRB1-dependent manner. Metoprolol acts during early phases of neutrophil recruitment by
impairing structural and functional rearrangements needed for productive engagement of
circulating platelets, resulting in erratic intravascular dynamics and blunted inﬂammation.
Depletion of neutrophils, ablation of Adrb1 in haematopoietic cells, or blockade of PSGL-1, the
receptor involved in neutrophil–platelet interactions, fully abrogated metoprolol’s infarct-
limiting effects. The association between neutrophil count and microvascular obstruction is
abolished in metoprolol-treated AMI patients. Metoprolol inhibits neutrophil–platelet
interactions in AMI patients by targeting neutrophils. Identiﬁcation of the relevant role of
ADRB1 in haematopoietic cells during acute injury and the protective role upon its modulation
offers potential for developing new therapeutic strategies.
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H
eart attack (acute myocardial infarction, AMI) is one of
the principal manifestations of cardiovascular disease and
a chief contributor to mortality and morbidity worldwide.
The main determinant of poor outcome post AMI is the extent of
irreversible injury (infarct size). The mainstay of AMI treatment
is rapid reperfusion to restore blood ﬂow, which reduces
complications and improves survival. However, reperfusion itself
accelerates and exacerbates the inﬂammatory response associated
with myocardial injury1. Thus, the injury inﬂicted on the
myocardium during AMI is the result of ischaemia and
reperfusion processes, and is known as ischaemia/reperfusion
(IR) injury. The development of effective therapies to reduce
myocardial IR injury is an unmet clinical need2.
The injured myocardium is inﬁltrated by circulating neutro-
phils, and these cells are critically involved in myocardial
IR injury3–7. In an inﬂammatory milieu, neutrophils bind to
platelets and red blood cells, forming plugs7. Upon reperfusion,
these plugs are dispersed into the microcirculation, where they
form embolisms, precluding tissue perfusion despite blood ﬂow
restoration in the large coronary arteries. This phenomenon,
known as microvascular obstruction (MVO), is a major
contributor to IR injury and infarct size1. Moreover, neutrophil
inﬁltration into acutely damaged organs is dependent on their
interaction with platelets8, and these interactions are critical to
the formation of harmful co-aggregates and the initiation of
inﬂammatory-like responses before tissue inﬁltration3,8. Overall,
neutrophil dynamics (including neutrophil–platelet interactions)
are an attractive therapeutic target for the prevention of IR injury.
The intravenous (i.v.) administration of the selective
b1-adrenergic receptor (ADRB1) antagonist metoprolol has been
shown to reduce infarct size and improve long-term cardiac
function after AMI in the recent METOCARD-CNIC trial9,10.
The mechanism underlying metoprolol’s cardioprotective
effect remains unclear11. Identifying this mechanism could have
signiﬁcant implications for the understanding of IR and the
development of novel infarct-limiting therapies. The adrenergic
system is critically involved in inﬂammatory reactions12,13.
In particular, the inﬂammatory response of neutrophils
involves the de novo production and release by these cells of
catecholamines12,13. Induced catecholamine stress (as during
ischaemia) alters neutrophil trafﬁcking14–16 and promotes
formation of neutrophil–platelet co-aggregates17.
We hypothesized that pre-reperfusion i.v. metoprolol admin-
istration alters neutrophil dynamics, resulting in a dampened
inﬂammatory response, less severe reperfusion injury and smaller
infarcts. Here we show that pre-reperfusion administration of i.v.
metoprolol to AMI patients signiﬁcantly reduces the incidence of
MVO, and moreover that metoprolol inhibits deleterious
neutrophil inﬂammatory responses both in patients and in
animal models of IR. The infarct-limiting effect of metoprolol is
abolished in neutrophil-depleted mice and when neutrophils are
prevented from interacting with platelets. The beneﬁcial effects of
metoprolol are also abolished by genetic ablation of Adrb1 and
are rescued by restitution of Adrb1 expression only in
haematopoietic cells. These results identify the neutrophil
dynamics as the target of the cardioprotective effect of metoprolol
against myocardial IR injury.
Results
Intravenous metoprolol reduces MVO in AMI patients. The
METOCARD-CNIC trial recruited patients with an ongoing
acute ST-segment elevation AMI and randomized them to receive
i.v. metoprolol (15mg) or control before reperfusion18. A total of
220 AMI patients underwent a cardiac magnetic resonance
(CMR) imaging exam 1 week after AMI. To study the potential
mechanisms underlying the infarct-limiting effect of metoprolol9,
we analysed the 1-week CMR data to evaluate the extent of
MVO. MVO was deﬁned as the absence of contrast wash-in
inside the delayed gadolinium-enhanced area19, and was
quantiﬁed as grams of left ventricle (LV) (Fig. 1a,b and
Supplementary Fig 1a,b). Patients treated with metoprolol
during ongoing AMI had a 40% lower extent of MVO (Fig. 1c).
This signiﬁcant effect was maintained after adjusting for factors
potentially affecting MVO by performing linear multiple
regression analysis and including sex, age, ischaemia duration,
diabetes, and use of thrombectomy or glycoprotein IIb/IIIa
inhibitors as covariates. To exclude the possibility that this effect
simply reﬂected the reduction in total infarct size9, MVO was
further assessed as a percentage of the infarcted area (total late
gadolinium enhanced area). Metoprolol-treated patients had
24% less infarct-normalized MVO than control patients
(Fig. 1d). As expected, the extent of MVO was signiﬁcantly
associated with poor long-term outcome, evaluated as chronic
ventricular performance (Supplementary Fig. 1c). These data
suggest that MVO reduction might be involved in the
cardioprotective effect of metoprolol administration in patients
during ongoing AMI.
Intravenous metoprolol dampens neutrophilial–MVO association
in AMI. White blood cell (WBC) and neutrophil counts during
an AMI are known to be associated with larger infarct sizes and
extensive MVO20–22. We explored these associations in
AMI patients from the METOCARD-CNIC trial. We found
a signiﬁcant positive correlation between absolute leukocyte
count on admission and the extent of MVO on CMR: the higher
the leukocyte count, the larger the extent of MVO (Fig. 2a).
We further studied the association of the different WBC
subpopulations and MVO. As expected, neutrophil count was
signiﬁcantly correlated with the extent of MVO (Fig. 2b).
Conversely, there was no sign of association between other
WBC subpopulations and MVO: lymphocyte, monocyte,
eosinophil or platelet counts did not correlate with the extent
of MVO (Fig. 2e). Next, we studied the effect of metoprolol on
WBCs and on the association between these and MVO.
Metoprolol treatment was not associated with any different in
WBC count nor in any WBC subpopulation (Supplementary
Table 1). Of note, we found a signiﬁcant interaction between
metoprolol treatment and the correlation between leukocyte
count and MVO: the signiﬁcant positive correlation between
neutrophil count and the extent of MVO was only present in
control patients (that is, not receiving metoprolol); in patients
receiving i.v. metoprolol before reperfusion there was no sign of
association between total leukocyte or neutrophil counts and the
extent of MVO (Fig. 2c,d). These results suggest that the
administration of i.v. metoprolol during ongoing AMI do not
affect the circulating levels of WBCs but modulates the impact of
neutrophils on MVO.
Metoprolol blunts neutrophil inﬁltration in experimental IR.
To identify the factors underlying the metoprolol-induced
reduction in MVO within the reperfused myocardium, we
examined a mouse model of in vivo myocardial IR injury
(Fig. 3a). Given the observed modulator effect of i.v. metoprolol
in the association between neutrophil count and MVO in patients
suffering an AMI, we focused our attention into this cell
population. We ﬁrst tested the infarct-limiting effect of
metoprolol in wild-type mice by occluding the left anterior
descending (LAD) coronary artery for 45min followed by
reperfusion. Mice were randomized to receive a single i.v. bolus
(50 ml) of metoprolol (10mM) or vehicle (saline) 35min after
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ischaemia onset (10min before reperfusion). Infarct size was
evaluated at 24 h reperfusion by TTC staining and normalized to
area at risk (AAR, negative Evans blue staining). Metoprolol-
treated mice had signiﬁcantly smaller infarcts (as % of AAR) than
vehicle-treated mice (Fig. 3b–d). Next, we examined mice
carrying a GFP reporter in myeloid derived cells (LysM-GFP).
LysM-GFP mice underwent the myocardial IR procedure and
were randomized to receive i.v. metoprolol or vehicle. Capillary
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Figure 1 | Metoprolol administration during ongoing AMI reduces MVO in patients. (a) METOCARD-CNIC trial scheme: patients with ongoing
ST-segment elevation myocardial infarction (STEMI) were recruited and randomized to receive metoprolol (15mg i.v. doses) or control before reperfusion.
A total of 220 patients were evaluated for MVO by cardiac magnetic resonance (CMR) imaging 1 week after AMI and 202 patients for an additional
CMR at long-term LVEF 6 months after AMI for ventricular function assessment. (b) Representative CMR exams (short-axis covering the entire left
ventricle (LV) from base to apex), showing signiﬁcant differences in 1-week MVO between a control patient (left) and a metoprolol-treated patient (right).
Lower panels show detailed views of the boxed images, revealing MVO (blue area, automatic quantiﬁcation), deﬁned as the absence of contrast wash-in
inside the delayed gadolinium-enhanced area (red, semiautomatic quantiﬁcation). Yellow arrowheads indicate MVO in the LV wall. (c) Quantiﬁcation of
MVO in grams of left ventricle. (d) Quantiﬁcation of MVO relative to the infarcted area (%). Dots represent values for individual patients: 114 in the control
group (grey) versus 106 in the metoprolol group (blue). Data are means±s.e.m. and compared by unpaired Student’s t-test.
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obliteration (a histological surrogate for MVO) and leukocyte
inﬁltration were quantiﬁed at 6 h post-reperfusion (Fig. 3e–m).
Metoprolol administration during ongoing AMI resulted in a
signiﬁcant reduction of capillary obliteration by circulatory cell
plugins when evaluated at 6 h post-reperfusion (Fig. 3e,f).
Confocal microscopy analyses revealed a signiﬁcant reduction in
the number of myeloid cells plugins (LysM-GFPþ particles)
and percentage of LysM-GFPþ area within the LV sections,
indicating rapid inhibition of leukocyte recruitment and protec-
tion of lumen vessel patency (Fig. 3g, Supplementary Fig. 2a–d
and Supplementary Movie 1). Temporal (6 and 24 h) evaluation
of myeloid-derived cells inﬁltration into injured myocardium
showed a persistent abrogation of neutrophil inﬁltration
(Fig. 3h–m and Supplementary Movie 2) and a differential
relative proportion of different myeloid cells in hearts from
metoprolol and vehicle-treated mice (Fig. 3j and Supplementary
Fig. 3). These mouse experiments conﬁrm the clinical ﬁndings
that pre-reperfusion metoprolol administration during ongoing
AMI limits infarct size and reduces MVO, and further show that
metoprolol reduces neutrophil inﬁltration, suggesting neutrophils
as a potential target in this cardioprotective effect.
Metoprolol does not protect from AMI in the absence of
neutrophils. Catecholamine-stimulation of bARs alters neu-
trophil function, cytokine release and neutrophil–platelet aggre-
gate formation17,23,24, processes associated with aggravated injury
during AMI (refs 25–27). To decipher the role of neutrophils in
the protection afforded by metoprolol during ongoing AMI, we
evaluated the effect of the drug in the absence of neutrophils.
Neutrophil depletion in mouse peripheral blood was achieved by
administration of an anti-Ly6G mAb over 2 days8,28. After
neutrophil depletion, animals were subjected to myocardial IR,
and infarct size was evaluated at 24 h post-reperfusion (Fig. 3n).
Conﬁrming earlier reports29, neutrophil-depleted mice had
smaller infarcts than controls. Administration of metoprolol to
these mice during ongoing AMI did not reduce infarct size
(Fig. 3o–q). The abrogation of the cardioprotective effect of
metoprolol conﬁrms circulating neutrophils as a target of the
beneﬁcial effect associated with this pharmacological therapy.
Metoprolol inhibits neutrophil migration by targeting ADRB1.
The effect of metoprolol on primary neutrophils’ function was
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Figure 2 | Metoprolol abrogates neutrophil count positive association with extent of MVO. Sensitivity analysis of the association between MVO and
leukocyte and subpopulations count on admission from METOCARD-CNIC trial patients. (a,b) Association between MVO and absolute leukocyte or
neutrophil count on admission. Grey dots represent individual values and line linear relationship. (c,d) Linear regression comparison between MVO and
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evaluated in a chemokine-induced transwell migration assay
and by evaluation of the chemotactic FPR activator-peptide,
W-peptide30, -induced reactive oxygen species (ROS) production
assay31. First, neutrophils were exposed across the transwell ﬁlter
to the chemoattractant CXCL1 in the presence or absence of
metoprolol for 1.5 h, and migration through the transwell
membrane was quantiﬁed by ﬂow cytometry. Metoprolol
inhibited baseline and epinephrine-stimulated neutrophil
migration towards CXCL1, reducing migration to the same
level in both cases (Fig. 4a). Second, ROS production in vitro was
measured using DHR 123 and W-peptide activation. ROS
production was tested in metoprolol-treated and untreated
neutrophils with and without W-peptide stimulation.
Metoprolol-treated neutrophils presented signiﬁcant decreased
oxidative burst compared to the non-treated cells after
stimulation (Fig. 4b,c). Metoprolol alone had no effect on ROS
endogenous production.
Metoprolol is a selective ADRB1-blocker, and ADRB1
signalling has been shown to mediate some of the pro-inﬂam-
matory response of monocytes32. Neutrophils and monocytes
are both myeloid derived cells, and we therefore reasoned
that ADRB1 might be involved in the anti-migratory effect of
metoprolol. Adrb1 mRNA expression in fresh and viable isolated
neutrophils was conﬁrmed by PCR in wild-type mice and
absence in neutrophils from Adrb1-knockout mice (Adrb1KO)
(Supplementary Fig. 4a–c). In vitro, the -epinephrine-mediated
a
45 min
Ischaemia Reperfusion
24 hMetoprolol
Vehicle
6 h
IS/AAR
or staining
WT
LysM-GFP+
60
0
20
40
60
AA
R
 (%
LV
)
0
20
40
IS
 (%
AA
R)
b
*
MetoprololVehicle
NSWT
d
Vehicle 
In
fa
rc
t s
ize
(T
TC
)
Metoprolol
AA
R
(E
va
ns
 B
lue
)
l
c
0.0 0.5 2.0
**Metoprolol
Vehicle
Capillary
obliteration
1.0 1.5f
e
6 h
6 h
g
M
ye
lo
id
 P
la
te
le
t N
uc
le
us
 M
em
br
an
e Vehicle Metoprolol
3D 3D
6 h 6 h
Vehicle MetoprololSham
Neutrophil Cardiomyocyte Lamininl
0
20
40
60
Metoprolol
Vehicle
0
20
40
60
Metoprolol
Vehicle
NS
Vehicle 
In
fa
rc
t s
ize
(T
TC
)
AA
R
(E
va
ns
 B
lue
)
MetoprololIn
fa
rc
t s
ize
 (%
AA
R)
AA
R
 (%
LV
)
p qo
l
Dapi LysM Ly6G Merged 
M
et
op
ro
lo
l
Ve
hi
cl
e
M
et
op
ro
lo
l
Ve
hi
cl
e
24
 h
 re
pe
rfu
sio
n
6 
h 
re
pe
rfu
sio
n
k
Vehicle
Metoprolol
Depletion
+ Ly6G-Ab
n
45 min
Ischaemia Reperfusion
24 hMetoprolol
Vehicle
WT
ih
Vehicle Metoprolol
6 h 24 h
0
25
50
75
100
125
150
Myeloid
*
*
Neutrophil
*
*
N
o.
 o
f c
el
ls 
pe
r i
m
ag
e
6 h 24 h
0
25
50
75
100
%
 N
eu
tro
ph
ils
6 h 24 h
N
o.
 o
f c
el
ls 
pe
r i
m
ag
e
0
25
50
75
100
125
150
j
*
Vehicle
Metoprolol
0
1
2
3
**
24 h
Ly
sM
+ 
(%
AA
R)
Metoprolol
Vehiclem
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms14780 ARTICLE
NATURE COMMUNICATIONS | 8:14780 | DOI: 10.1038/ncomms14780 |www.nature.com/naturecommunications 5
migration- and -W-peptide-mediated ROS production-inhibitory
effect of metoprolol was lost in Adrb1KO neutrophils (Fig. 4a–c).
b2-adrenergic receptor-knockout mice (Adrb2KO) was not
involved in the effects observed after metoprolol administration
(Supplementary Fig. 5).
We next explored whether metoprolol directly inhibits the
capacity of neutrophils to inﬁltrate tissues in vivo. For this, we
ﬁrst used a model of thioglycolate-induced peritonitis (Fig. 4d).
Thioglycolate induces massive leucocyte migration into the
peritoneal cavity within the ﬁrst 16 h (Supplementary Fig. 6a),
with the majority of inﬁltrating cells being neutrophils (Supple-
mentary Fig. 6b–d). Metoprolol i.v. administration sharply
inhibited thioglycolate-induced neutrophil inﬁltration into the
peritoneal cavity of wild-type mice (Fig. 4e,f), but the inhibitory
effect of metoprolol was lost in Adrb1KO mice (Fig. 4f and
Supplementary Fig. 6a,b).
To better deﬁne the cell compartment targeted by metoprolol,
we lethally irradiated Adrb1KO mice and restored haematopoiesis
with bone marrow (BM) transplanted from wild-type donors,
generating chimeric mice expressing ADRB1 only in circulating
cells. At 4 weeks after irradiation, transplanted animals presented
485% BM engraftment (Supplementary Fig. 7) and were
subjected to thioglycolate-induced peritonitis. The replenishment
of ADRB1 only in haematopoietic cells was enough to rescue the
anti-leucocyte-inﬁltration effect of metoprolol (Fig. 4g). Together,
these data show a direct effect of metoprolol on neutrophil
function and demonstrate that the presence of ADRB1 in
circulating cells is essential for the ability of metoprolol to reduce
neutrophil inﬁltration into injured tissue.
IR reduction by metoprolol involves haematopoietic cells’
ADRB1. We next investigated the involvement of ADRB1
blockade in haematopoietic circulating cells in the protective
effect of metoprolol in the infarcted myocardium. Adrb1KO mice
were subjected to myocardial IR and randomized to receive i.v.
metoprolol or vehicle during ongoing AMI (Fig. 4h). Unlike the
situation in wild-type mice, metoprolol did not limit infarct size
in Adrb1KO animals (Fig. 4i–k), demonstrating the critical role of
ADRB1 blockade in the cardioprotective effect. To demonstrate
the role of ADRB1 expression in haematopoietic circulating cells,
we repeated the myocardial IR protocol in the chimeras described
above (Adrb1KO mice transplanted with wild-type BM). The
presence of ADRB1 only in haematopoietic circulating cells was
sufﬁcient to restore susceptibility to the cardioprotective effect of
metoprolol (Fig. 4l–n). Conversely, transplant of Adrb1KO
BM into irradiated wild-type mice abrogated the protective
phenotype associated with metoprolol administration during
IR (Fig. 4o–q). These data conﬁrm the involvement of ADRB1
blockade in haematopoietic cells in the cardioprotection afforded
by metoprolol administration during AMI.
Metoprolol alters neutrophil dynamics in vivo. During acute
injury, neutrophils alter their morphology upon adhering to
the activated endothelium. These shape change or polarization,
permit intercellular interactions critical for the inﬂammatory
response in several conditions, including myocardial IR
(refs 8,33). Polarization of adhered neutrophils involves receptor
redistribution and the assembly of a rearward protruding
microdomain called the uropod, and is essential for the
integration of signals coming from the endothelium and
activated platelets before inﬁltration8. We were therefore
interested in investigating whether metoprolol impaired
neutrophil migration and inﬁltration through an effect on
neutrophil dynamics. For this, we used bi-dimensional and
3D intravital microscopy (IVM) to image cremaster muscle
vessels of mice treated with tumour necrosis factor-a (TNFa), an
inﬂammatory model in which the vast majority of recruited
leukocytes are neutrophils. Neutrophil behaviour was evaluated
3 h after administration of metoprolol or vehicle (Fig. 5a).
Notably, metoprolol reduced neutrophil migratory velocity,
accumulated crawling distance and directional movement
(Fig. 5b,c and online Supplementary Movie 3). Independent-
neutrophil 3D-reconstructions of live inﬂamed vessels showed
that metoprolol consistently disabled the intravascular behaviour
of neutrophils without disrupting polarization within activated
vessels, resulting in dramatic changes in cell morphology
(Fig. 5d–f) that correlated with their abnormal crawling
dynamics. These data show that metoprolol ‘stuns’ neutrophils,
resulting in altered dynamics and prevents the morphological
changes needed to initiate intercellular interactions and
subsequent tissue inﬁltration.
Metoprolol blocks PSGL1-dependent neutrophil platelet
interactions. Correct neutrophil polarization and organization of
an extruding microdomain that captures circulating platelets is
required to initiate tissue-damaging inﬂammation8. Indeed, plugs
of neutrophil–platelet co-aggregates in the microcirculation are a
major contributor to MVO in AMI and in other models
of injury1,8. We therefore explored the impact of metoprolol-
induced neutrophil stunning on neutrophil–platelet interactions.
Figure 3 | Metoprolol reduces neutrophil inﬁltration and capillary obliteration in murine IR. (a) Mouse model of myocardial IR. (b, c) Histological
evaluation of left ventricle (LV) area at risk (AAR) and infarct size (IS) in mice subjected to IR and randomized to receive metoprolol (blue) or vehicle
(white); NS stands for non-signiﬁcant. n¼8. (d) Representative images of LV slices showing AAR (negative for Evans Blue) in upper panels and extent of
necrosis (triphenyltetrazoliumchloride (TTC)-negative area in lower panels). (e) Capillary oblliteration quantiﬁed in H&E ten random images; n¼ 5–6.
(f) Representative H&E myocardial images at 6 h reperfusion showing disarrayed and abundant obstructed capillaries in the vehicle-treated sample;
metoprolol-treated samples show injury and nuclear condensation but no signs of MVO; green scale bars, 50mm. Detailed ampliﬁcation of the boxes show
obstructed capillaries indicated with black arrows; black scale bars, 10mm. (g) Confocal images from LV at 6 h after reperfusion onset showing massive
vascular neutrophil migration (LysM-GFP, green) and co-aggregates with platelets (CD41, red) vehicle- but not in metoprolol-treated mice; scale bar,
25mm. Next, ampliﬁed boxes indicating regions of capillary obstruction; scale bar, 10mm. Bottom yellow panels show computed 3D reconstructions.
(h,i) Myeloid-derived cell inﬁltration dynamics showing maintained attenuation in hearts from metoprolol-treated mice. n¼ 5. (j) Neutrophilic proportions
inﬁltrate dynamics. (k) Representative confocal images of LV sections taken from injured mice after 6 and 24 h reperfusion onset. Myeloid inﬁltration
(LysM-GFPþ , green) most of which are neutrophil (Ly6Gþ , red) is evident in vehicle-treated mice and signiﬁcantly attenuated in those from metoprolol-
treated mice; merged images show double positive cells (LysMþ /Ly6Gþ , that is, neutrophils). Scale bar, 50mm; n¼ 3–5. (l) Representative confocal
images of neutrophil inﬁltration 24 h after reperfusion onset. Vehicle-treated mice show massive myocardial neutrophil inﬁltration (LysM-GFPþ , green),
with dispersed cells attached to the injured cardiac ﬁbre membranes (a-actinin, red; laminin, grey). (m) LysMþ total area in the LV section as a %AAR;
scale bar, 20mm; n¼ 5–6. (n–q) Effect of metoprolol on limiting-infarct size in neutrophil-depleted mice. (n) Neutrophil depletion model. (o) Myocardial
area at risk (AAR). (p) Infarct size. (q) Representative transverse ventricular slices showing AAR and infarct size Data are means±s.e.m. *Po0.05;
**Po0.01, determined by the nonparametric Wilcoxon–Mann–Whitney test for each panel.
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Using the cremaster IVM model of TNFa-induced local
inﬂammation, we evaluated the acute neutrophil–platelet
inhibitory effect of metoprolol in polarized neutrophils (Fig. 5).
Metoprolol i.v. administration effectively inhibited interactions
with the uropod, but not the leading edge (Fig. 5g,h) and
rapidly reduced total neutrophil–platelet interactions (Fig. 5i–k).
IVM experiments in Adrb1KO mice revealed no differences
between metoprolol-treated and vehicle-treated mice, implicating
ADRB1 in the inhibitory effect of metoprolol on neutrophil–
platelet interactions (Fig. 5j).
Based on these ﬁndings, we hypothesized that inhibition of
neutrophil–platelet interactions underlies the inhibitory effect of
metoprolol on MVO after myocardial IR. To test this, we
ﬁrst evaluated the effect of metoprolol on neutrophil–platelet
0
20
40
60
NS
In
fa
rc
t s
ize
(T
TC
)
AA
R
(E
va
ns
 B
lue
)
In
fa
rc
t s
ize
 (%
AA
R)
0
20
40
60
In
fa
rc
t s
ize
 (%
AA
R)
Vehicle Metoprolol
In
fa
rc
t s
ize
(T
TC
)
AA
R
(E
va
ns
 B
lue
)
Vehicle 
In
fa
rc
t s
ize
(T
TC
)
AA
R
(E
va
ns
 B
lue
)
Vehicle Metoprolol
*
Metoprolol
Vehicle
0
20
40
60
β1KO
AA
R
 (%
LV
)
0
20
40
60
AA
R
 (%
LV
)
0
20
40
60
In
fa
rc
t s
ize
 (%
AA
R)
0
20
40
60
AA
R
 (%
LV
)
NS
Metoprolol
Vehicle
WT>β1KO
Metoprolol
Vehicle
WT
a
N
eu
tro
ph
il C
XC
L1
-
in
du
ce
d 
m
ig
ra
tio
n
Vehicle
Epinephrine
Metoprolol
Metoprolol+Epinephrine
0.0
0.5
1.0
1.5
2.0
2.5
NS
β1KO
* **
***
i
NS
R
el
at
iv
e 
ne
ut
ro
ph
ils
MetoprololVehicle
WT>WT
WT>β1KO
β1KO>WT
β1KO>β1KO
0.00
0.05
0.5
1.0
1.5
* *
g
FACS
IP Thioglycolate 16 h
Metoprolol
Vehicle
BMT
n
k
l
β1KO>WT
qo
45 min
Ischaemia Reperfusion
(IS evaluation)MetoprololVehicle
β1KO
WT>β1KO
β1KO>β1KO 24 h
h
Vehicle
Metoprolol
W-pep + Vehicle
W-pep + Metoprolol
Metoprolol
0 104105
Vehicle
Ly6G
R
ho
12
3
0
5
10
15 WT
***
*
**
NS
NS
NS
Ly
6G
+ 
ce
lls
R
O
S 
pr
od
uc
tio
n
β1KO
***3
6
9
12
15
0
WT
Vehicle Metoprolol
GR1
CD
11
5
MetoprololVehicle
d
FACS
IP Thioglycolate
Metoprolol
Vehicle
16 h
WT
β1KO
N
eu
tro
ph
ils
(10
5  
pe
r m
l)
NS
β1KO
c
e
f
p
m
j
1051040
b
Metoprolol
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms14780 ARTICLE
NATURE COMMUNICATIONS | 8:14780 | DOI: 10.1038/ncomms14780 |www.nature.com/naturecommunications 7
co-aggregate formation in mouse myocardial vessels after
experimental IR. Administration of metoprolol to wild-type mice
during ongoing AMI signiﬁcantly reduced the number of
neutrophils attached to the vessel wall (Fig. 6a,b) and the average
number of interacting platelets per neutrophil (Fig. 6c).
Neutrophil–platelet interactions during acute injury are
mediated by PSGL1 and signals delivered upon these contacts
promote subsequent neutrophil extravasation and injury to the
tissue8. Blockade of PSGL1 by pretreatment with PSGL1-mAB
(Fig. 6e) signiﬁcantly reduced infarct size in the myocardial
IR model, and administration of metoprolol during ongoing
AMI did not yield any further infarct-size reductions (Fig. 6f,g).
These data conﬁrm that metoprolol protects the infarcted
myocardium by uncoupling neutrophil recruitment and
polarization, thereby disrupting neutrophil–platelet interactions
and the downstream inﬂammatory response.
Metoprolol limits neutrophil–platelet aggregates in patients.
To investigate whether metoprolol alters neutrophil dynamics
and inhibits neutrophil–platelet interactions in humans, whole
blood drawn from healthy donors was incubated ex vivo with
epinephrine (5 mM) and increasing concentrations of metoprolol
(0, 2, 5mM). Samples were then stained, and neutrophil–platelet
co-aggregate formation was evaluated by ﬂow cytometry34–37
(morphological parameters, CD14neg, CD45þ , CD61þ ).
Metoprolol signiﬁcantly inhibited epinephrine-stimulated
neutrophil–platelet co-aggregate formation (Fig. 7a). The effect
of metoprolol in vivo was additionally studied in patients
undergoing elective coronary angioplasty for acute coronary
syndrome (ACS). Samples were collected before and after i.v.
administration of metoprolol (15mg) and circulating neutrophil–
platelet co-aggregates were assessed by ﬂow cytometry.
Metoprolol administration signiﬁcantly reduced the number of
neutrophil–platelet interactions (Fig. 7b). To elucidate whether
metoprolol was acting at the platelet level of action we evaluated
effect of metoprolol on platelet function through platelet
aggregation using light transmittance aggregometry in platelet-
rich plasma (PRP) (Supplementary Fig. 8a) or platelet activation
surface markers expression assay using ﬂow cytometry
(Supplementary Fig. 8b,c). Metoprolol did not show any
effect on platelet aggregation/activation, which together
with the aforementioned effects on neutrophil migration and
ROS-production suggests that the effect seen on neutrophil–
platelet co-aggregates was driven by a direct effect on neutrophils.
Discussion
Early metoprolol administration during AMI, given as an adjunct
to mechanical reperfusion has been shown to reduce infarct size
and ameliorate post-infarction severe cardiac dysfunction11,38.
Deﬁning the mechanisms underlying this cardioprotection is
therefore of great medical relevance since more efﬁcient and
speciﬁc protective strategies could be identiﬁed.
The ability of ADRB1 selective blockers to reduce infarct
size was tested decades ago in several clinical trials, but the
results were inconclusive1. However, most of these early studies
were performed in the context of non-reperfused AMI. The
advent of reperfusion as the treatment of choice for AMI changed
the mode of myocardial death: from unrelieved ischaemia to a
combination of ischaemia and reperfusion processes. Therefore
the potential cardioprotective effects of ADRB1 selective blockers
needed to be revisited in light of the current evidence of IR injury
during AMI (ref. 1). The ability of metoprolol to reduce
infarct size in the context of reperfused AMI was recently
evaluated in the METOCARD-CNIC trial. In this trial, early
i.v. metoprolol administration during ongoing AMI resulted
in a signiﬁcant reduction of infarct size9,39, and also signiﬁcantly
reduced the incidence of severe ventricular dysfunction and heart
failure readmissions10. Large animal studies conducted before the
METOCARD-CNIC trial showed that metoprolol reduces infarct
size only when administered before reperfusion40,41, suggesting
that metoprolol might reduce infarct size by inhibiting
reperfusion injury. The early studies, testing the infarct-limiting
properties of metoprolol in non-reperfused AMI, were
undertaken under the hypothesis that ADRB1-blockers would
reduce the extent of damage by a direct effect on cardiomyocytes
via reducing oxygen consumption. Although our large animal
study40 did not investigate the mechanism of metoprolol-
mediated protection, it did show that oxygen consumption was
similar in metoprolol- and vehicle-treated pigs. In addition, the
infarct-size reduction in metoprolol-treated pigs was associated
with reduced myeloperoxidase activity in the post-ischaemic
myocardium 24 h after reperfusion41. These ﬁndings challenged
the idea that metoprolol could reduce cardiac damages simply by
reducing myocardial oxygen consumption directly in the heart
and prompted us to investigate the cellular mechanisms
underlying the reperfusion-related injury-limiting effect of
metoprolol during IR.
There is ample evidence supporting the critical implication of
neutrophils in IR injury4,25,27,29,42,43. Neutrophils have two
deleterious effects in this context. First, neutrophils and
neutrophil–platelet plugs occlude microvessels, preventing
efﬁcient tissue perfusion: MVO. Second, neutrophils adhering
to the newly reperfused injured vessels inﬁltrate the
myocardium1, prompting deleterious processes associated
with reperfusion25,33. Our study conﬁrms these associations in
AMI patients: neutrophil count positively correlated with the
extent of MVO as evaluated by state-of-the-art MRI 1 week after
reperfusion. There exist weak pre-existing evidence linking
the action of metoprolol to neutrophils, including reductions in
Figure 4 | Metoprolol directly inhibits neutrophil deleterious function through a ADRB1-blockade. (a) Effect of metoprolol on CXCL1-induced migration
of fresh isolated primary neutrophils (Ly6Gþ ) from WTor Adrb1-knockout (b1KO) mice. CXCL1-stimulated cells were incubated with vehicle, epinephrine
(10mM), metoprolol (10mM) and epinephrineþmetoprolol; n¼4 independent experiments. NS, stands for non-signiﬁcant. (b,c) Inhibitory effect of
metoprolol on W-peptide-induced ROS production on fresh isolated primary neutrophils (Ly6Gþ ) from WTor b1KO mice. Mean ﬂuorescent intensity of
Rho123 in Ly6Gþ neutrophils after W-peptide stimulation. n¼6 independent experiments; ﬂow cytometry plots illustrate reduced expression of Rho123 in
metoprolol-treated neutrophils. (d–f) Effect of metoprolol on limiting-thioglycolate-induced peritoneal inﬁltration on WT and b1KO mice. (e) Flow
cytometry plots illustrating reduced inﬁltration of neutrophils (CD115neg; GR1þ ) in metoprolol-treated mice. Absolute neutrophils detected per ml of
inﬁltrate at 16 h after thioglycolate injection in WTmice (n¼ 7–9) or b1KO mice (n¼ 5). (g) Effect of metoprolol on thioglycolate-induced neutrophil
inﬁltration in the four BMT groups. Protocol scheme for thioglycolate-induced peritonitis assay after bone-marrow transplants (BMT) between WT and
b1KO mice, evaluating the inﬂuence of the presence or absence of ADRB1 in circulating cells. Data are normalized to vehicle; n¼4–9. (h) Protocol scheme
for IR experiments in chimeric animals after BMT, evaluating the infarct-limiting effect of metoprolol in the presence or absence of ADRB1 in circulating cells.
(i–q) Area at risk (AAR) and infarct size, as well as representative images of Evans blue and TTC staining in metoprolol-treated and vehicle-treated b1KO
and chimeras (WT bone marrow transplanted into b1KO mice and reverse transplants). Infarct size is reduced by metoprolol only when circulating cells
express b1-adrenergic receptor; n¼ 9 (i,j), n¼ 8 (l,m), n¼ 5–6 (o,p). Data are means±s.e.m. *Po0.05; **Po0.01; ***Po0.001, determined by the
nonparametric Wilcoxon–Mann–Whitney test or using the one-way ANOVA and Holm Sidak’s post-hoc multiple comparisons method.
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post-IR myeloperoxidase activity in pig myocardium41 and rat
spinal cord44, and inhibition of sepsis-induced inﬂammation in
mice45. The data here presented from patients randomized in
a controlled clinical trial are the ﬁrst human evidence linking
metoprolol with altered neutrophil behaviour in vivo. We show
that the strong positive correlation between neutrophil count and
MVO was abolished in patients receiving i.v. metoprolol before
reperfusion. The fact that metoprolol-treated patients’ high
neutrophil count was not associated with the extent of MVO
suggests an altered neutrophil dynamics during acute injury.
Some preclinical studies have suggested an association between
metoprolol exposure and altered neutrophil dynamics41,44,45;
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however, the cellular mechanism responsible for this effect has
remained unknown. Our results from the in vitro transwell
migration assays conﬁrm previous studies showing the ability of
metoprolol to inhibit migration of isolated neutrophils46. Also,
our in vitro data conﬁrm previous studies showing that
metoprolol was able to inhibit ROS production from
neutrophils47. Our in vitro results showing migration inhibition
by metoprolol are reinforced by the acute in vivo murine
peritonitis model, in which a single metoprolol i.v. injection
abrogates neutrophil inﬁltration into the peritoneal cavity.
Furthermore, the studies with Adrb1KO mice provide evidence
for a critical involvement of the ADRB1 axis in the effects of
metoprolol. In the transwell assays, metoprolol had no effect on
the migration of Adrb1KO neutrophils, and in the peritonitis
assay, the inhibitory effect of metoprolol on neutrophil
inﬁltration was lost in Adrb1KO mice. The rescue of this
inhibitory effect in chimeric animals in which Adrb1 is expressed
only in circulating cells demonstrates that the cellular target of
metoprolol action is of haematopoietic origin, and rules out an
involvement of other compartments. Moreover, the ﬁndings in
the peritonitis model were conﬁrmed in the myocardial IR model,
with metoprolol signiﬁcantly reducing neutrophil inﬁltration into
the injured myocardium of wild-type but not Adrb1KO mice, and
rescue of the protective effect in the Adrb1KO after wild-type BM
transplant. Finally, we ruled out any involvement of ADRB2 on
the effect exerted by metoprolol. Altogether, these results
demonstrate the essential role of neutrophil ADRB1 blockade in
the protective effect of metoprolol against myocardial IR injury.
Our data are in discrepancy with a prior study suggesting
that metoprolol abrogated neutrophil migration in vitro in an
apparently ADRB1-independent manner46. In that study
authors reported that metoprolol was able to inhibit neutrophil
migration even in the presence of the b-adrenergic receptor
agonist orciprenaline, while in our study we have used a genetic
ablation toll (that is, Adrb1KO mice), which ensures the
absence of ADRB1.
Upon acute injury, neutrophils recruited to injured vessels
initiate inﬂammation by scanning for activated platelets present
in the circulation, establishing interactions with them through
PSGL1 exposed on neutrophil protrusions8. The IVM confocal
imaging analysis demonstrated that metoprolol prevents the
exposure of functional PSGL1 clusters, which are essential for
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interaction with platelets. These events correlated with alterations
in neutrophil properties essential for inﬁltration, including
migratory velocity and directionality. In agreement with
these data, in the mouse myocardial IR model, metoprolol
altered neutrophil 3D structure and reduced the numbers of
neutrophil–platelet co-aggregates that occluded myocardial
vessels. The inability of metoprolol to provide additional
protection after blockade of neutrophil–platelet interactions
with the anti-PSGL1 mAB is compelling evidence for
interference in this interaction as the mechanism underlying
the infarct-limiting action of metoprolol during myocardial IR in
mice. The demonstration that metoprolol inhibits neutrophil–
platelet interactions in healthy volunteers and ACS patients
suggests that this mechanism also operates in humans. There is
controversy on the direct effect of metoprolol on platelet
aggregation. Some studies suggested that metoprolol was
able to inhibit ADP- and epinephrine-mediated platelet
aggregation48, but recent studies did not show any anti-platelet
effect of metoprolol49. In line with the latter evidence, in our
study we found that metoprolol had no effect on platelet
aggregation or in platelet activation in healthy volunteers. These
data strongly suggest that the inhibitory effect of metoprolol on
neutrophil–platelet co-aggregates was driven by a direct effect on
neutrophils. In our ﬂow cytometry studies we deﬁned a positive
neutrophil–platelet interaction as CD14neg, CD45þ , CD61þ
particles. It should be noted that there are more speciﬁc
neutrophil markers and thus our selection is a limitation of
these experiments. However, given that all data (human and
mouse) point to the same direction, we think this limitation did
not have an impact on the conclusions obtained in these
experiments.
The role of neutrophils in experimental IR injury is well
established; however, the negative results of clinical trials with
anti-inﬂammatory therapies (for example, C5a (refs 50,51),
CD-18 (ref. 52)) dampened hopes for this pharmacological
strategy3, and suggested that parallel mechanisms driving
myocardial injury were at play. The demonstration that neutro-
phil dynamics in general and neutrophil–platelet interactions in
particular are the target for the protective actions of metoprolol
administered to patients during AMI reinstates neutrophils as
a potential target for the therapeutic reduction of infarct size.
Methods
Human cardiac magnetic resonance imaging. The METOCARD-CNIC trial
(NCT01311700) recruited patients suffering an AMI during hospital transit to
undergo mechanical reperfusion by primary angioplasty. Patients were randomized
to receive i.v. metoprolol (up to 15mg) or no drug (control). Patients underwent
two CMR studies: 1 week and 6 months after AMI. Images were acquired with
a 3.0 Tesla magnet (Achieva Tx, Philips Medical Systems) with vectorcardiographic
gating and a dedicated cardiac 32-channel phased-array surface coil. The extent of
MVO was measured in the 1-week CMR study; to detect and quantify MVO,
a delayed enhancement imaging was performed 10min after gadolinium
contrast injection, using a T1-weighted 2-D Inversion Recovery Turbo Field Echo
(2D IR-TFE) sequence. Myocardial necrosis was deﬁned by the extent of abnormal
gadolinium enhancement, whereas MVO was deﬁned as black-hypoenhanced areas
within the bright-hyperenhanced regions. CMR analysis was undertaken by
operators blinded to treatment allocation at the Centro Nacional de Investigaciones
Cardiovasculares Carlos III (CNIC). Myocardial necrosis and MVO were quanti-
ﬁed by semiautomatic delineation with dedicated software (QMass MR 7.6; Medis,
Leiden, the Netherlands). Total MVO was quantiﬁed as grams of LV. To correct for
infarct size, MVO was also expressed as a percentage of the infarcted area.
Mouse procedures. Experimental procedures were approved by the CNIC Animal
Care and Ethics Committee and regional authorities. IR, thioglycolate-induced
peritonitis and IVM experiments were performed in 8–13-week-old wild-type
male C57BL/6 mice. b1-adrenergic receptor (Adrb1) knockout (KO; Adrb1KO)
mice were in a mixed background. b2-adrenergic receptor (Adrb2) knockout
(KO; Adrb2KO) mice were in a C5BL/6 background. For the BM transplant
experiments, Adrb1KO mice were backcrossed with mice expressing DsRed under
the control of the b-actin promoter to facilitate evaluation of BM engraftment.
Male and female mice were used as donors in BM transplant procedures, but
only males were used in myocardial IR and thioglycolate-induced peritonitis
experiments. All animals were randomized to receive a single i.v. injection (50 ml)
of metoprolol-tartrate (10mM) or vehicle (saline). Histological evaluation of
injured myocardium in the myocardial IR model was performed in lysozyme
M-GFPþ (LysM-GFP)53 male mice. Intravascular neutrophil and neutrophil–
platelet interactions were scored manually in the myocardium. Neutrophils were
depleted in C57BL/6 male by i.v. injections of 50 mg anti-mouse Ly6G 24 and 48 h
before the myocardial IR procedure28. For in vivo blocking of P-selectin
glycoprotein ligand-1 (PSGL1), 50 mg of anti-PSGL1 antibody (clone 4RA10) was
i.v. injected 15min after ischaemia onset. Mice were maintained under pathogen-
free conditions in a temperature-controlled room and a 12-h light–dark cycle at the
CNIC animal facilities. Chow and water were available ad libitum.
Reagents. Metoprolol-tartrate (M5391), Evans blue, triphenyltetrazolium
chloride, DAPI (D8417-1MG), Mowiol mounting medium (81381), anti-laminin
(L9393), anti-a-actinin (A7732), dihydrorhodamine 123 (D1054) were obtained
from Sigma-Aldrich. Dylight-650-conjugated anti-1A8 Ly6G (BE0075-1) and
anti-PSGL1 antibody (clone 4RA10) from BioXcell. Anti-CD41 (12-04-11-83)
and anti-CD115 (12-1152-83) were obtained from ebioscience. O.C.T. was
obtained from Tissue-Tek. Qiagen RNeasy Plus Mini Kit (74136). Percoll Plus
(17-5445-02) and Ready-to-go RT-PCR Beads (27-9259-01) from GE Healthcare.
CXCL1 was obtained from (453-KC-010) from R&D Systems. W-peptide
(WKYMVM, 1799) from Tocris. Thioglycolate (BD211716) and anti-GP IIb/IIIa
from BD Biosciences. Anti-GR1 (ab2557) was obtained from Abcam and AF-647
(A-21472) from Molecular Probes. Anti-CD45-FITC from Miltenyi Biotec,
Germany. PC5-conjugated anti-CD14, anti-CD61 PC7 and Versalyse solution were
obtained from Beckman Coulter.
Mouse model of myocardial IR injury. Male 8–12-week-old mice were subjected
to 45min occlusion of the LAD coronary artery followed by 6 or 24 h of
reperfusion. For infarct size evaluation, reperfusion was maintained for 24 h.
For analysis of MVO, neutrophil inﬁltration and neutrophil–platelet interactions,
reperfusion was maintained for 6 or 24 h as indicated. The IR procedure was
performed as previously described54. Brieﬂy, fully asleep animals were intubated
and temperature controlled throughout the experiment at 36.5 C to prevent
hypothermic cardioprotection. Thoracotomy was then performed and the LAD was
ligated with a nylon 8/0 monoﬁlament suture for 45min. The electrocardiogram
was monitored (MP36R, Biopac Systems Inc.) to conﬁrm total coronary artery
occlusion (ST-segment elevation) throughout the 45min ischaemia. Ten minutes
before reperfusion onset, mice were randomized to receive a single i.v. injection
(50 ml) of metoprolol-tartrate (10mM) or vehicle (saline) through the femoral vein.
Dose of metoprolol was chosen after a dose response study (Supplementary Fig. 9).
At the end of reperfusion, the chest was closed and animals were kept with
100% O2 and analgesized with buprenorphine (S.C., 0.1mg per kg) until the
end of reperfusion.
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Figure 7 | Metoprolol inhibits neutrophil–platelet interactions in
patients. (a) Effect of metoprolol on neutrophil–platelet co-aggregate
formation in epinephrine-stimulated whole blood from healthy volunteers
(n¼ 20). Whole blood was incubated in vitro with epinephrine 5 mM and
metroprolol (Meto, concentrations in mM). (b) In vivo effect of metoprolol
(up to15mg i.v.) on the number of neutrophil i.v.platelet co-aggregates in
acute coronary syndrome (ACS) patients scheduled for coronary angio-
plasty. Blood was drawn before and after metoprolol i.v. administration;
n¼ 6 ACS patients. Pre, before i.v. administration; Post, after i.v. admini-
stration. Data are means±s.e.m. *Po0.05; **Po0.01, determined by
one-way ANOVA and Holm Sidak’s post-hoc multiple comparisons method.
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Mouse infarct size quantiﬁcation. At the end of follow up, mice were re-anes-
thetized and re-intubated, and the LAD coronary artery was re-occluded by ligating
the suture in the same position as the original infarction54. Animals were then
killed and rapidly 1ml of 1% (w per v) Evans Blue dye was infused i.v. to delineate
AAR: myocardium lacking blood ﬂow, that is, negative for blue dye staining.
The heart was then harvested, LV was isolated, cut into transverse slices (5–7 1-mm
thick slices per LV) and both sides were imaged. Sections post-Evans blue staining
present two different areas: one palish negative for Evans blue perfusion,
delineating AAR, and another blueish (positive Evans blue) area indicating remote
tissue. In order to differentiate infarcted from viable tissue, same slices were
incubated in triphenyltetrazolium chloride (TTC, 1% (w per v) diluted in PBS) at
37 C for 15min in constant shacking. The slices were then re-photographed and
weighed. Post TTC incubation, Evans blue staining clears out and slices present
two areas: one necrotic (palish negative to TTC staining) and one reddish alive
(positive to TTC staining). Regions negative for Evans Blue staining (AAR) and
for TTC (infarcted myocardium) were quantiﬁed using ImageJ (NIH, Bethesda,
MD, USA) by blinded observer. Percentage values for AAR and infarcted
myocardium were corrected to mg independently for each slice. Absolute AAR and
infarct size were determined as the mg:mg ratio of AAR:LV and infarcted
myocardium:AAR, respectively. Animals exceeding 80% of IS were excluded
assuming absence of reperfusion.
Hearts processing for histology. At the end of reperfusion, LysM-GFP mice were
re-anesthetized, placed in a supine position, their ventral thoracic regions wiped
with 70% alcohol and killed by cervical dislocation. Next, 10ml of PBS with
heparin (50U per ml) was gently infused through the vena cava to avoid blood
clots. Hearts were then removed and cut into 1mm-thick transverse sections and
ﬁxed with 2% PFA in PBS for 24 h at 4 C.
Heart slices (1mm) designated to histopathological analysis of capillary
obliteration were dehydrated through an ethanol series, cleared in xylene,
embedded in parafﬁn wax and consequently sectioned (4 mm) for staining with
haematoxylin and eosin. All immunohistochemical procedures were performed
with an automated autostainer (Autostainer Plus, Dako) at the CNIC Histology
Unit. Images were digitally scanned (Nanozoomer-RS C110730, Hamamatsu) and
examined with image analysis software (Tissuemorph, Visiopharm) by blinded
observers. Once the lesion was identiﬁed, 10–12 images ( 20) were taken at
random, and capillary obliteration was scored from 0 to 2, with 0 indicating the
absence of capillary obliteration and 2 indicating presence of obstruction in all
capillaries.
Confocal microscopy. Sections designated for immunoﬂuorescence staining and
confocal microscopy were post-ﬁxed overnight and placed in 30% sucrose for 24 h
and included in O.C.T. (Tissue-Tek). Serial 4 mm coronal sections were cut on
a freezing microtome (Leica CM1950) and stored in cryoprotective solution.
Sections designated for evaluation of neutrophil inﬁltration of the injured area
were washed in PBS for 15min and incubated with DAPI (1:1,000) at room
temperature for 5min, washed in PBS twice and mounted in Mowiol mounting
medium. Images of full short-axis heart sections were acquired with an inverted
confocal laser imaging system (Zeiss LSM7004 4-Laser) and reconstructed with
Zeiss ZEN reprocessing software. Presence of Lysm-GFPþ cells analysis was
performed with ImageJ (NIH) by blinded observers. Values of total GFPþ surface
were normalized to LV section surface. A second set of sections were stained
with Dylight-650-conjugated anti-1A8 Ly6G and DAPI for quantiﬁcation of
speciﬁc neutrophil identiﬁcation and temporal inﬁltration analysis. Eight
independent 40 were evaluated from injured myocardium from each animal,
and presence of myeloid derived cells (LysMþ ), neutrophils (LysMþ Ly6Gþ )
and monocytes (LysMþ Ly6Gneg) were identiﬁed and analysed using ImageJ
by blinded observers. Four animals were stained for basal quantiﬁcation. Some
sections were stained with anti-laminin to stain cell membranes (1:150) and
anti-a-actinin to visualize sarcomeres in cardiac ﬁbres (1:200) for detailed
illustration of neutrophil inﬁltration in the injured myocardium. Images were
post-processed and edited using the Imaris software (Bitplane AG, Switzerland) as
indicated below.
Neutrophil–platelet interactions staining in infarcted mouse heart was adapted
from Sreeramkumar et al.8. Brieﬂy, OCT-embedded heart slices were cut into
50mm sections, washed in PBS for 15min and incubated for 20min at room
temperature in blocking buffer (PBS containing 10% BSA and 2% goat serum).
For detailed visualization and characterization of the injured zone, cell
membranes were stained with anti-laminin (1:150) and platelets were stained
with PE-conjugated anti-CD41 (1:200). Primary and secondary antibodies were
diluted 1:200 in blocking buffer, and incubations were conducted for 1 h at room
temperature. Nonspeciﬁc staining was assessed by omission of primary antibody.
Samples were counterstained with DAPI and mounted in Mowiol. Images were
acquired with a laser-scanning confocal imaging system (Leica SP8 or SP5) at the
CNIC Microscopy Unit and post-processed with Leica Las AF and Imaris software
(Bitplane AG, Switzerland). Independent vessels (7–9) were evaluated for each
animal, and intravascular neutrophil and neutrophil–platelet interactions were
scored manually.
Neutrophil puriﬁcation and Adrb1 expression. Adrb1 expression in circulating
neutrophils was examined in blood drawn from wild-type or Adrb1KO mice
20min after injection of heparin (50 ml of 50U per ml). Whole blood was
ﬁltered and pooled, and polymorphonuclear leukocytes were puriﬁed by
gradient-centrifugation (800g, 20min, 4 C) in 65% Percoll Plus in Hanks balanced
salt solution (HBSS). Cells were washed in PBS and residual erythrocytes were
lysed using hypotonic buffer. Neutrophils were washed and resuspended in HBSS.
Before RNA isolation, neutrophil identity was conﬁrmed by ﬂow cytometry
(anti-1A8 Ly6G) and viability evaluated.
Total RNA from whole hearts, BM and puriﬁed neutrophils samples was
isolated with the Qiagen RNeasy Plus Mini Kit. RNA (1–2 mg) was reverse
transcribed using Ready-to-go RT–PCR Beads (27-9259-01, GE Healthcare).
PCR was performed with 40 cycles of 95 C for 12 s and 60 C for 1min. All PCR
reactions were done in triplicate. Primers for Hprt and Adrb1 were as follows:
mHprt_fw-50-GAGGAGTCCTGTTGATGTTGCCAG-30 , mHprt_rv-50-GGCTGG
CCTATAGGCTCATAGTGC-30 ; mAdrb1_fw-50-GTGGGTAACGTGCTG
GTGAT-30 , mAdrb1_rv-50-GAAGTCCAGAGCTCGCAGAA-30 . Amplicons
generated in the qPCR were loaded on to an agarose gel to conﬁrm single
PCR products.
Migration transwell assay. The ability of leukocytes to migrate towards
chemokine (C-X-C motif) ligand 1 (CXCL1) was assessed using a modiﬁcation of
the method of Villablanca et al.55. Brieﬂy, wild-type or Adrb1KO mice were
heparinized (50ml of 50U per ml, IP) and 20min later blood was collected and
ﬁltered, and residual erythrocytes were lysed with hypotonic buffer. PBS-washed
leukocytes of the same genotype were pooled and resuspended in RPMI containing
10% FBS and the appropriate treatment: saline (vehicle control), 10 mM
epinephrine (positive control), 10 mM metoprolol-tartrate, or a combination
of epinephrine and metoprolol. Transwell inserts (6.5mm, 5.0 mm pore size
(3421; Corning Costar Corporation)) were pretreated with 50 ml RPMI for 20min
and placed in 24-well-plates before seeding cells (100 ml; B1 105; 490%
viability). Lower compartments (wells) were ﬁlled with 600 ml DMEM medium
containing 0.04 ng per ml CXCL1 to induce directional movement. Spontaneous
migration was assessed in wells lacking CXCL1. After incubation at 37 C for 1.5 h,
cells in the lower compartment were collected and neutrophils (Ly6Gþ cells) were
evaluated by ﬂow cytometry. Each independent experiment was conducted with
leukocytes pooled from nine animals, and each of the ﬁve conditions was run with
four replicates. Mean spontaneous migration was subtracted from the migration
value of each well, and neutrophil migration was expressed as a percentage of
the total number of neutrophils seeded in the upper chamber at the start of the
experiment. For comparison between experiments and genotypes, migration was
normalized to the mean control (vehicle) value.
Neutrophil oxidative burst assay. Blood from wild-type or Adrb1KO mice was
collected in heparinized tubes and distributed in 100 ml aliquots, erythrocytes were
lysed with hypotonic buffer. After centrifugation leucocytes were ﬁrst washed and
then re-suspended in high glucose phenol red free DMEM. Cells were then
incubated for 50min with or without metoprolol-tartrate 100 mM at 37 C.
As previously described30,31, dihydrorhodamine 123 (DHR 123, 1 mM), which
converts to the ﬂuorescent product rhodamine 123 (Rho 123) upon oxidation
was then added to the medium and cells were stimulated with the chemotactic FPR
activator-peptide, w-peptide 1 mM (WKYMVM, 1799 Tocris). After 20min
incubation at 37 C the reaction was stopped in ice and cells were washed in cold
HBSS containing DAPI 0.1 mg per ml (D8417, Sigma). Mean ﬂuorescent intensity
for Rho 123 was evaluated for neutrophils (Ly6Gþ cells) alive (DAPIneg) by ﬂow
cytometry.
Model of thioglycolate-induced peritonitis. To assess the ability of metoprolol to
inhibit neutrophil recruitment, we used a well-established thioglycolate-induced
peritonitis model (see Fig. 3). Wild-type mice were intraperitoneally injected with
1ml of thioglycolate and immediately randomized to receive a single 50 ml i.v.
injection of vehicle or metoprolol-tartrate (10mM). Sixteen hours later, 100 ml of
blood from each animal was collected into EDTA tubes for later haematological
analysis in a haematocytometer (Pentra 80). Next, animals were killed, 2ml PBS
was injected intraperitoneally and distributed manually for 30 s to detach inﬁltrated
circulatory cells. Next, another 8ml PBS was injected to facilitate collection of
6ml peritoneal exudate. Exudates were gently centrifuged, and cells were washed
twice with PBS and incubated for 1 h with anti-GR1 (1:200) and PE-conjugated
anti-CD115 (1:200). After washing with PBS, cells were incubated for 30min
with anti-rat 647 to detect GR1. Cell nuclei were stained with DAPI. All samples
were analysed by ﬂow cytometry for exactly 30 s of constant ﬂow. Neutrophil
recruitment efﬁciencies are presented as neutrophils per ml of exudate for each
independent animal.
To evaluate the role of ADRB1 in different compartments, we performed the
same experiments in Adrb1KO mice and generated cohorts of chimeric mice by
transplantation with BM cells from wild-type and Adrb1KO donors. Four weeks
after BM transplantation, chimerism was evaluated by ﬂow cytometry as the
percentage of donated cells. Animals with chimerism below 85% were discarded;
those with chimerism above 85% underwent the thioglycolate-induced peritonitis
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protocol followed by randomization to receive either i.v. vehicle or metoprolol
(10mM). To compare between the different chimeric groups, the mean value for
each metoprolol-treated group was normalized to the mean for the vehicle-treated
group.
Bone marrow transplant. BM transplants protocols were adapted from
Casanova et al.28. Recipient mice from Adrb1KO or wild-type genotypes
(DsRedþ or DsRed- as appropriate) were lethally irradiated (13Gy in two doses)
before reconstitution with donor BM. Donor BM was collected from mice of the
appropriate genotype by ﬂushing both tibiae and femurs into PBS containing 2mM
EDTA (PEB buffer). Contaminating erythrocytes were lysed with hypotonic buffer.
Engraftment in recipient animals was assessed by ﬂow cytometry 3–4 weeks after
transplantation. Animals bled for engraftment evaluations were rested for 1 week
before any other procedure.
Flow cytometry. Neutrophil purity for in vitro migration assay and Adrb1
expression analysis was evaluated by incubating cells with Dylight-650-conjugated
anti-1A8 Ly6G and with DAPI to assess viability. Mouse primary blood leukocytes
from peritonitis experiments were incubated with anti-Gr1 conjugated with
AF-647 and with PE-conjugated anti-CD115 and DAPI. Neutrophils were gated on
the basis of Gr1-positive and CD115-negative staining in a FACS Canto-3L ﬂow
cytometre equipped with DIVA software (BD Biosciences). Doublet discrimination
and viability (negative to DAPI) was assessed for every sample. Data were analysed
with FlowJo (Ashland) software by blinded observer. All experiments were
conducted at the CNIC-Cellomics Unit.
Intravital microscopy. IVM of the cremaster muscle was performed after
intrascrotal injection of TNFa (0.5mg R&D Systems)8, followed immediately by
injection of a single i.v. bolus of metoprolol (10mM) or vehicle, and neutrophil
behaviour was evaluated 3 h after stimulus. In some experiments metoprolol was
injected 3 h after treatment with TNF-a and images immediately acquired for
analysis (see Fig. 4). The IVM system was built by 3i (Intelligent Imaging
Innovations, Denver, CO, USA) on an Axio Examiner Z.1 workstation
(Zeiss, Oberkochen, Germany) mounted on a 3-Dimensional Motorized Stage
(Sutter Instrument, Novato, CA, USA). This set up allows precise computer-
controlled lateral movement between XY positions and a Z focusing drive for
confocal acquisition. The microscope is equipped with a CoolLED pE wideﬁeld
ﬂuorescence LED light source system (CoolLED Ltd. UK) and a quad pass ﬁlter
cube with a Semrock Di01-R405/488/561/635 dichroic and a FF01-446/523/600/
677 emitter. We used a plan-Apochromat  40 W NA1.0N/0 objective (Zeiss).
Images were collected with a CoolSnap HQ2 camera (6.45 6.45-mm pixels,
1,392 1,040 pixel format; Photometrics, Tucson, AZ, USA). For confocal
high-speed IVM, we used laser stacks for 488, 561 and 640 nm beams coupled with
a confocal scanner (Yokogawa CSUX-A1; Yokogawa, Japan); images were acquired
at 0.5 mm Z-intervals. Image acquisition was coordinated and ofﬂine data
analysis facilitated with SlideBook software (Intelligent Imaging Innovations),
run on a Dell Precision T7500 computer (Dell Inc., Round Rock, TX, USA). For
three-dimensional analysis we used the 3D surface view function to determine the
position of the CD62Lþ clusters relative to the cell body and the lumen. Six to ten
venules per mouse were analysed 210 to 300min after TNF-a treatment by
acquisition of ﬂuorescence (Cy3/561 channels for phycoerythirn, FITC/488
channels for FITC and Cy5/640 channels for allophycocianin) and bright-ﬁeld
images with 2 2 for 2min. For double staining with PE- and FITC-conjugated
antibodies, acquisition was facilitated in single (FITC) and quad (PE) ﬁlters in
order to avoid bleed-through of ﬂuorescent signals between channels. For in vivo
labelling of neutrophils and platelets surface molecules, ﬂuorescently labelled
antibodies were injected intravenously (anti-CD62L-FITC, anti-Ly6G-APC and
anti-CD41-PE; 0.5–1.25 mg per mouse). Images were post-processed and edited
using the Imaris software (Bitplane AG, Switzerland) as indicated below.
Analysis of blood cell interactions. Platelets in the inﬂamed cremaster muscle
were visualized as CD41-labelled cells and quantiﬁed as reported8. Brieﬂy, we
deﬁned the uropod of adherent neutrophils as the domain staining positive for
CD62L, and the leading edge as the CD62L-negative pole forming multiple
protrusions and showing guided movement. Six to ten venules per mouse were
recorded, and platelet interactions with neutrophils were counted and analysed
manually at the two distinct domains of the polarized neutrophil with the help of
Slidebook software.
Analysis of tracking of crawling neutrophils. Time-lapse movies of crawling
neutrophils were analysed with ImageJ, which includes the Manual Tracking and
the Chemotaxis and Migration Tool plugins. For each movie we ﬁrst adjusted
channel intensities and converted them into RGB format. Movies were rotated so
that the vessels and the blood ﬂow were positioned horizontally and oriented
left-right. When necessary, the Background subtraction and Image stabilization
pre-stablished plugins were applied to eliminate noise and reduce tissue twitching,
respectively. Both plugins were set up with xy calibration values, which depend on
the camera and microscope parameters, to convert pixels into linear measures, as
well as the time interval value between movie frames (3 s). Each polarized
neutrophil (identiﬁed by a clear polarized morphology or uropod staining) was
tracked manually for 1min using the Manual Tracking Plugin, which generated a
data set with the respective xy track coordinates. We then used the Chemotaxis and
Migration Tool to plot and the velocity (mm per s), accumulated distance (mm),
euclidean distance (mm) and directionality of the tracks obtained. The Euclidean
distance is the length of the straight-line segment connecting the initial and
ﬁnishing points, whereas the accumulated distance is the total length of the path
covered by the cell. Directionality measures how straight the cell track is, and is
calculated as the ratio of euclidean distance to accumulated distance.
Analysis of 3D reconstructions of polarized neutrophils. We measured the 3D
features of intravascular neutrophils using Imaris Software (Bitplane, Oxford, UK).
From the parameters provided by the ImarisCell module, we selected prolate
ellipticity by obtaining the lengths of the three semi-axes, which correspond with
the Ellipsoid axis parameters. A prolate ellipsoid (cigar-like shape) is one for which
the polar radius is greater than the equatorial radius. For 3D cell reconstructions,
we used the ImarisCell module to deﬁne the cell body. We then segmented a region
of interest to enclose an individual cell within this region, so that the subsequent
reconstruction ﬁtted the real cell structure. Afterwards, the respective source
channel from which the cells had to be computed was selected. For reconstruction
analysis, we chose the Ly6G-APC channel as it is a membrane-bound protein that
yields a strong signal and allows a good rendering of the actual cell morphology.
ImarisCell module determines the cell threshold by calculating voxel (3D pixel)
intensities from the enclosed cell and comparing them with the background
intensity in the enclosed sub-region. To obtain the height-to-length ratios, we
visually established the cell orientation with respect to the vessel wall surface.
Sections of each polarized neutrophil were analysed to manually measure the
height of the cell and maximum length (from the top view) with respect to the
vessel wall. For this purpose, we used Imaris Section View, which shows the
coordinates in the three display areas (xy top view, zy lateral view and xz front
view), and the Extended Crosshairs of the Section View, which in turn allows
selection of the z-stack planes to visualize the entire cell (not just one plane or
section) in the three views. A snapshot of these three views from a single cell
was taken and imported into ImageJ, where height and maximum length were
measured from the different views after setting the capture scale.
Human blood sampling. Functional tests were performed in blood samples from
20 volunteers (36±6 years, 15 men). Exclusion criteria were as follows: any
antiplatelet, anticoagulant or anti-inﬂammatory drug taken within the 2 previous
weeks; abnormal platelet or leukocyte count; or any history of abnormal bleeding,
thrombosis, or active inﬂammatory disease. Written consent was obtained from all
volunteers. Blood samples were collected into polypropylene tubes containing
sodium citrate from an antecubital vein with a 21-gauge needle, discarding the ﬁrst
2ml to avoid platelet activation. Blood was collected between 8:00 and 10:00 after
overnight fasting. Samples were processed immediately. ACS patients were
recruited at our cath-lab (both genders, age o80) from among those referred for
coronary angiogram and subsequent percutaneous coronary intervention. Exclu-
sion criteria were as follows: active treatment with b-blockers; any situation which
might make it imprudent to administer an i.v.-b-blocker; asthma or chronic
obstructive lung disease; bradycardio (HR o55 b.p.m.); heart failure or valvular
heart disease; atrial ﬁbrillation requiring antiarrhythmic therapy; renal failure with
creatinineZ2mg per ml; liver disease with bilirubinZ2mg per ml; acute illness of
any malignancy; pregnancy or nursing; body mass index Z27 kg per m2; previous
severe adverse reaction to b-blockers; concomitant use of other antithrombotic
drugs such as anticoagulants, dypiridamol, ticlopidine or cilostazol; treatment
before the intervention with GP IIb/IIIa inhibitors, or need for nonsteroid
anti-inﬂammatory drugs. Written informed consent was obtained from all patients
enrolled. Blood samples were collected from a femoral artery catheter into
polypropylene tubes containing sodium citrate, discarding the ﬁrst 2ml. Samples
were processed immediately.
Human neutrophil–platelet interactions evaluation. Human citrated blood was
diluted 1:5 in HEPES-Tyrode’s* (5mM hydroxyethylpiperazineethane-sulfonic
acid (HEPES), 137mM NaCl, 2.7mM NaHCO3, 0.36mM NaH2PO4, 2mM
NaH2PO4, 2mM CaCl2, 5mM glucose, bovine albumin 0.2%. pH¼ 7.4) and
incubated with 0, 2 or 5 mM metoprolol for 10min. Then, 5ml of diluted blood
was incubated with 5 mM epinephrine for 10min. Unstimulated and epinephrine-
stimulated samples were stained with PC5-conjugated anti-CD14 anti CD45-FITC
and anti-CD61 PC7 for 20min at room temperature in the dark. Erythrocytes were
lysed for 10min using Versalyse solution. Appropriate mouse isotype controls were
used for each antibody. Flow cytometry analysis was performed with a Gallios
cytometer (Beckman Coulter, Miami, FL, USA). Leukocytes were by CD45-FITC
staining. Neutrophils identiﬁcation was adapted from refs 34,35 and performed by
morphological parameters (side scatter) and negative staining for CD14-PC5 but
positive staining for CD45-FITC. Neutrophil–platelet conjugates were identiﬁed as
bivariate histogram particles negative for CD14-PC5 and positive to CD61-PC7
(refs 36,37). The acquisition process was stopped after collection of 5,000
monocytes. Data are expressed as the percentage of neutrophil–platelet aggregates.
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All experiments were conducted at the Hospital Universitario Clı´nico San Carlos,
Madrid.
Human platelet function evaluation. Platelet aggregation was assessed using light
transmittance aggregometry in PRP by the turbidimetric method in a four-channel
aggregometer (Chrono-Log 490 Model, Chrono-Log Corp., Havertown, PA, USA)
according to standard protocols. The PRP was obtained from citrated blood at
centrifuge (800 r.p.m.) for 10min and platelet-poor plasma was obtained after
a second centrifugation (2,500 r.p.m.) for 10min. PRP will be adjusted to 250,000
per ml with autologous plasma. PRP was incubated with metoprolol 2 and 5 mM or
saline buffer for 15min and then stimulated using epinephrine (5 mM). Light
transmission was adjusted to 0% with PRP and to 100% with platelet-poor plasma
for each measurement. Curves were recorded during 5min and platelet aggregation
was determined as the maximal percent change in light transmittance.
Platelet function was determined by assessing platelet activation as surface
expression of activated GP IIb/IIIa (Becton Dickinson) and P-Selectin using
ﬂow cytometry. Whole blood from healthy donors were drawn into trisodium
citrate tubes diluted with Hepes-tyrodes-buffer (0.2% BSA) to a ﬁnal volume of
1:8:1 (blood: Hepes-tyrodes:citrate). Diluted blood was incubated with metoprolol
2 and 5 mM or saline for 15min. Following activation with epinephrine (5 mM)
samples were incubated for 20min with polyclonal PAC1-FITC conjugated or
PE-conjugated anti-CD62P. Appropriate isotype controls were used in each case.
Platelet activation was expressed as the percentage of platelets positive for antibody
binding. Platelets were gated on the basis of light scatter and CD61 antibody
expression. Activated platelets were deﬁned as the percentage of expressing
the activated conﬁrmation of PAC1 binding and P-selectin (CD62P). Data
were expressed as the percentage of platelets positive for antibody binding.
All experiments were conducted at the Hospital Universitario Clı´nico San Carlos,
Madrid.
Statistics. Data are represented as mean±s.e. of the mean (s.e.m.), and analysed
using Prism software (Graph pad, Inc.) and Stata (Stata 12.0; StataCorp LP,
College Station, TX, USA). Comparisons between two groups were performed
by using the unpaired two-tailed Student’s t-test or the nonparametric
Wilcoxon–Mann–Whitney test as appropriate. Comparisons between more than
two groups were performed by using the one-way ANOVA. The P-value was
adjusted with the Holm Sidak’s multiple comparison test. Multiple linear regression
analysis was used to study the inﬂuence of metoprolol on MVO, adjusted for
factors potentially affecting MVO such as sex, age, ischaemia duration, diabetes,
use of thrombectomy or glycoprotein IIb/IIIa inhibitors. Test for linear trend after
one-way ANOVA was used to study the relationship between LVEF at 6 months
and MVO quartiles at 1 week. Power calculations were applied to obtain
statistically signiﬁcant at P values below 0.05 signiﬁcant. *Po0.05, **Po0.01,
***Po0.001.
Study approval. All studies in patients and volunteers were approved by the ethics
committee of Hospital Clı´nico San Carlos, Madrid. Written informed consent was
received from all participants before inclusion in the study.
Data availability. The data that support the conclusions of this study are available
from the corresponding author on reasonable request.
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